EGFR and neoplasm: Pembrolizumab, a monoclonal immunoglobulin antibody against PD‐1, was recently approved by the US Food and Drug Administration for monotherapy for patients with stage III NSCLC who are not candidates for surgical resection or definitive chemoradiation, or have metastatic NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase genomic tumor aberrations.